AV8 Ventures has launched with a $180 million second fund to help drive emerging technologies in AI-driven health, mobility and enterprise.
AV8 Ventures has invested in 20 companies with a focus on the US since its launch in 2018.
“We are humbled by the continued support from Allianz and our founders who have chosen to partner with us,” said George Ugras, Managing Director at AV8.
“We will continue to focus on funding seed-stage start-ups modernizing enterprise, healthcare and financial services with deep technology.
“The additions to our team since the launch of our first fund with Baris Aksoy joining us from Google and Ruchita Sinha from Sanofi have brought us tremendous domain knowledge augmented by our venture advisors.”
“AV8 complements Allianz’s digital investment activities and plays an important role in our investment strategy by bringing insights into emerging, early-stage technologies in areas such as cybersecurity, healthcare and digitization.
“We look forward to deepening our partnership with AV8 and are excited about the start-ups this new fund will support,” said Ivan de la Sota, Chief Business Transformation Officer, Allianz SE.
Co-founder and CEO of Delfi Diagnostics Victor Velculescu added, “Early diagnosis is the best way to beat cancer. We spun out Delfi to commercialize the first affordable and most accurate technology to meet this ambitious goal.
“We met AV8 early in our formation stages and have been impressed with the depth and sincerity of their engagement. They have helped us with our strategy, and have been true partners who share our vision for beating cancer.”
